Apoptotic and Molecular Mechanisms of Carthamidin in Breast Cancer Therapy: An Integrated In Vitro and In Silico Study.

IF 2.4 4区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY
Selvakumari Palani, John Joseph, Priyadharshan Sridhar, Giridharan Bupesh, Konda Mani Saravanan, Rajkuberan Chandrasekaran
{"title":"Apoptotic and Molecular Mechanisms of Carthamidin in Breast Cancer Therapy: An Integrated In Vitro and In Silico Study.","authors":"Selvakumari Palani, John Joseph, Priyadharshan Sridhar, Giridharan Bupesh, Konda Mani Saravanan, Rajkuberan Chandrasekaran","doi":"10.1007/s12033-024-01331-2","DOIUrl":null,"url":null,"abstract":"<p><p>The current study examines the anticancer properties of the chemical carthamidin in breast cancer through in-vitro and in silico analysis. This study's results demonstrated that carthamidin strongly inhibited the proliferation of MCF 7 cells in vitro, as evidenced by an IC50 value of 128.65 µg/mL at 24 h, determined using the MTT test. Laser confocal microscopy utilizing AO/EB labeling validated apoptotic effects through upregulating pro-apoptotic cell markers. At the same time, the ROS assay demonstrated elevated ROS production in the treated cells. LDH leakage was corroborated by leakage analysis, revealing high LDH levels at 100 µg/mL. The cellular growth parameters were subsequently examined via flow cytometry, showing that the cell cycle was halted in the G0/G1 phase, with 82.9% of the cells residing there. The molecular docking research demonstrated that carthamidin displayed a significant binding affinity with Notch receptors - NOTCH 1-4 and p53, with binding scores ranging from - 5.027 to - 7.402 kcal/mol. The results suggest that carthamidin has therapeutic potential in inducing apoptosis and impairing cancer cells, warranting further investigation in breast cancer treatments.</p>","PeriodicalId":18865,"journal":{"name":"Molecular Biotechnology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Biotechnology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12033-024-01331-2","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The current study examines the anticancer properties of the chemical carthamidin in breast cancer through in-vitro and in silico analysis. This study's results demonstrated that carthamidin strongly inhibited the proliferation of MCF 7 cells in vitro, as evidenced by an IC50 value of 128.65 µg/mL at 24 h, determined using the MTT test. Laser confocal microscopy utilizing AO/EB labeling validated apoptotic effects through upregulating pro-apoptotic cell markers. At the same time, the ROS assay demonstrated elevated ROS production in the treated cells. LDH leakage was corroborated by leakage analysis, revealing high LDH levels at 100 µg/mL. The cellular growth parameters were subsequently examined via flow cytometry, showing that the cell cycle was halted in the G0/G1 phase, with 82.9% of the cells residing there. The molecular docking research demonstrated that carthamidin displayed a significant binding affinity with Notch receptors - NOTCH 1-4 and p53, with binding scores ranging from - 5.027 to - 7.402 kcal/mol. The results suggest that carthamidin has therapeutic potential in inducing apoptosis and impairing cancer cells, warranting further investigation in breast cancer treatments.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Biotechnology
Molecular Biotechnology 医学-生化与分子生物学
CiteScore
4.10
自引率
3.80%
发文量
165
审稿时长
6 months
期刊介绍: Molecular Biotechnology publishes original research papers on the application of molecular biology to both basic and applied research in the field of biotechnology. Particular areas of interest include the following: stability and expression of cloned gene products, cell transformation, gene cloning systems and the production of recombinant proteins, protein purification and analysis, transgenic species, developmental biology, mutation analysis, the applications of DNA fingerprinting, RNA interference, and PCR technology, microarray technology, proteomics, mass spectrometry, bioinformatics, plant molecular biology, microbial genetics, gene probes and the diagnosis of disease, pharmaceutical and health care products, therapeutic agents, vaccines, gene targeting, gene therapy, stem cell technology and tissue engineering, antisense technology, protein engineering and enzyme technology, monoclonal antibodies, glycobiology and glycomics, and agricultural biotechnology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信